Pregabalin and Oxcarbazepine — Competitive Intelligence Brief

Pregabalin and Oxcarbazepine (Pregabalin and Oxcarbazepine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug. Area: Neurology.

marketed Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine) Neurology Small molecule

Target snapshot

Pregabalin and Oxcarbazepine (Pregabalin and Oxcarbazepine) — Ju Seok Ryu. This combination product uses pregabalin to modulate calcium channels and reduce neurotransmitter release, while oxcarbazepine blocks sodium channels to stabilize neuronal membranes and reduce seizure activity.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pregabalin and Oxcarbazepine TARGET	Pregabalin and Oxcarbazepine	Ju Seok Ryu	marketed	Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug	Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine)
Venlafaxine and Lamotrigine	Venlafaxine and Lamotrigine	University Health Network, Toronto	marketed	SNRI + anticonvulsant combination	Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation
nortriptyline + topiramate	nortriptyline + topiramate	University of California, Irvine	marketed	Tricyclic antidepressant + anticonvulsant combination	Norepinephrine transporter, serotonin transporter, voltage-gated sodium channels, GABA receptors
Phentermine / Topiramate Oral Product	Phentermine / Topiramate Oral Product	University of Florida	phase 3	Sympathomimetic amine / Anticonvulsant combination	Norepinephrine release (phentermine); carbonic anhydrase inhibition and GABA modulation (topiramate)
Levetiracetam/Clonazepam	Levetiracetam/Clonazepam	Assistance Publique - Hôpitaux de Paris	phase 3	Anticonvulsant combination (SV2A modulator + benzodiazepine)	SV2A (synaptic vesicle protein 2A) and GABA-A receptor
Placebo matched phentermine/topiramate	Placebo matched phentermine/topiramate	VIVUS LLC	phase 3	Sympathomimetic amine + anticonvulsant combination	Norepinephrine release (phentermine); carbonic anhydrase, GABA receptors, glutamate receptors (topiramate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug class)

1. Ju Seok Ryu · 1 drug in this class